Silence Therapeutics (SLN) Competitors

Silence Therapeutics logo
$19.80 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$19.80 +0.00 (+0.03%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SLN vs. IONS, CRSP, RLAY, CDNA, and TNGX

Should you buy Silence Therapeutics stock or one of its competitors? Silence Therapeutics's main competitors and comparable companies include Ionis Pharmaceuticals (IONS), CRISPR Therapeutics (CRSP), Relay Therapeutics (RLAY), CareDx (CDNA), and Tango Therapeutics (TNGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Silence Therapeutics compare to Ionis Pharmaceuticals?

Silence Therapeutics (NASDAQ:SLN) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Silence Therapeutics has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Silence Therapeutics currently has a consensus price target of $24.00, indicating a potential upside of 21.21%. Ionis Pharmaceuticals has a consensus price target of $75.71, indicating a potential upside of 170.31%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Silence Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silence Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
Ionis Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.78

Ionis Pharmaceuticals has a net margin of -56.98% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -102.72% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Silence Therapeutics-8,943.86% -102.72% -43.70%
Ionis Pharmaceuticals -56.98%-120.62%-16.99%

In the previous week, Ionis Pharmaceuticals had 33 more articles in the media than Silence Therapeutics. MarketBeat recorded 39 mentions for Ionis Pharmaceuticals and 6 mentions for Silence Therapeutics. Ionis Pharmaceuticals' average media sentiment score of 0.11 beat Silence Therapeutics' score of 0.05 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Silence Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ionis Pharmaceuticals
6 Very Positive mention(s)
5 Positive mention(s)
14 Neutral mention(s)
7 Negative mention(s)
0 Very Negative mention(s)
Neutral

Silence Therapeutics has higher earnings, but lower revenue than Ionis Pharmaceuticals. Silence Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics$560K2,197.45-$88.61M-$1.07N/A
Ionis Pharmaceuticals$944M4.94-$381.39M-$3.32N/A

Summary

Ionis Pharmaceuticals beats Silence Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to CRISPR Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

CRISPR Therapeutics has a net margin of -1,812.07% compared to Silence Therapeutics' net margin of -8,943.86%. CRISPR Therapeutics' return on equity of -25.59% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Silence Therapeutics-8,943.86% -102.72% -43.70%
CRISPR Therapeutics -1,812.07%-25.59%-17.89%

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Silence Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

Silence Therapeutics currently has a consensus target price of $24.00, suggesting a potential upside of 21.21%. CRISPR Therapeutics has a consensus target price of $72.93, suggesting a potential upside of 80.65%. Given CRISPR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than Silence Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silence Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.65

Silence Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics$560K2,197.45-$88.61M-$1.07N/A
CRISPR Therapeutics$3.51M1,115.64-$581.60M-$4.74N/A

In the previous week, CRISPR Therapeutics had 7 more articles in the media than Silence Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 6 mentions for Silence Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.12 beat Silence Therapeutics' score of 0.05 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Silence Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CRISPR Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

CRISPR Therapeutics beats Silence Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Silence Therapeutics (NASDAQ:SLN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Relay Therapeutics presently has a consensus price target of $27.00, indicating a potential upside of 56.34%. Silence Therapeutics has a consensus price target of $24.00, indicating a potential upside of 21.21%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Relay Therapeutics is more favorable than Silence Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relay Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.86
Silence Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

Relay Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market.

Silence Therapeutics has lower revenue, but higher earnings than Relay Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relay Therapeutics$15.35M248.60-$276.48M-$1.51N/A
Silence Therapeutics$560K2,197.45-$88.61M-$1.07N/A

In the previous week, Relay Therapeutics had 6 more articles in the media than Silence Therapeutics. MarketBeat recorded 12 mentions for Relay Therapeutics and 6 mentions for Silence Therapeutics. Relay Therapeutics' average media sentiment score of 0.96 beat Silence Therapeutics' score of 0.05 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relay Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Silence Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Relay Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Relay Therapeutics' return on equity of -40.25% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Relay TherapeuticsN/A -40.25% -36.82%
Silence Therapeutics -8,943.86%-102.72%-43.70%

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Relay Therapeutics beats Silence Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Silence Therapeutics compare to CareDx?

CareDx (NASDAQ:CDNA) and Silence Therapeutics (NASDAQ:SLN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

CareDx presently has a consensus target price of $70.33, indicating a potential downside of 4.59%. Silence Therapeutics has a consensus target price of $24.00, indicating a potential upside of 21.21%. Given Silence Therapeutics' higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than CareDx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CareDx
0 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.67
Silence Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

In the previous week, CareDx had 11 more articles in the media than Silence Therapeutics. MarketBeat recorded 17 mentions for CareDx and 6 mentions for Silence Therapeutics. CareDx's average media sentiment score of 0.62 beat Silence Therapeutics' score of 0.05 indicating that CareDx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CareDx
5 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Silence Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CareDx has a net margin of 25.86% compared to Silence Therapeutics' net margin of -8,943.86%. CareDx's return on equity of 9.74% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CareDx25.86% 9.74% 7.35%
Silence Therapeutics -8,943.86%-102.72%-43.70%

CareDx has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CareDx$379.80M10.20-$21.35M$2.3930.85
Silence Therapeutics$560K2,197.45-$88.61M-$1.07N/A

CareDx has a beta of 2.51, suggesting that its stock price is 151% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

98.7% of Silence Therapeutics shares are held by institutional investors. 2.4% of CareDx shares are held by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

CareDx beats Silence Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Silence Therapeutics compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Silence Therapeutics (NASDAQ:SLN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Tango Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market.

Tango Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Tango Therapeutics' return on equity of -30.34% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tango TherapeuticsN/A -30.34% -28.28%
Silence Therapeutics -8,943.86%-102.72%-43.70%

Silence Therapeutics has lower revenue, but higher earnings than Tango Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tango Therapeutics$62.38M65.66-$101.59M-$1.37N/A
Silence Therapeutics$560K2,197.45-$88.61M-$1.07N/A

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tango Therapeutics currently has a consensus target price of $45.54, suggesting a potential upside of 88.41%. Silence Therapeutics has a consensus target price of $24.00, suggesting a potential upside of 21.21%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tango Therapeutics is more favorable than Silence Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tango Therapeutics
2 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.65
Silence Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

In the previous week, Tango Therapeutics had 25 more articles in the media than Silence Therapeutics. MarketBeat recorded 31 mentions for Tango Therapeutics and 6 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.05 beat Tango Therapeutics' score of 0.04 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tango Therapeutics
7 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Silence Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Tango Therapeutics beats Silence Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Silence Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLN vs. The Competition

MetricSilence TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.23B$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-18.5025.6832.7626.82
Price / Sales2,197.4516.068.565.70
Price / CashN/A22.9521.0121.90
Price / Book15.004.184.463.72
Net Income-$88.61M-$24.15M$3.52B$393.10M
7 Day Performance0.05%-7.25%-5.47%-4.73%
1 Month Performance128.11%-5.98%-4.57%-7.14%
1 Year Performance195.52%-7.72%-1.79%-7.51%

Silence Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLN
Silence Therapeutics
2.9907 of 5 stars
$19.80
flat
$24.00
+21.2%
+189.9%$1.23B$560KN/A88
IONS
Ionis Pharmaceuticals
3.5748 of 5 stars
$27.77
-10.4%
$78.00
+180.9%
-60.9%$4.61B$944MN/A1,402
CRSP
CRISPR Therapeutics
2.6616 of 5 stars
$45.15
-9.8%
$69.69
+54.3%
-23.1%$4.38B$3.51MN/A393
RLAY
Relay Therapeutics
2.7808 of 5 stars
$19.96
-2.1%
$27.00
+35.3%
+174.6%$4.37B$15.35MN/A218
CDNA
CareDx
1.4532 of 5 stars
$80.77
-4.3%
$64.40
-20.3%
+362.5%$4.24B$379.80M33.80765

Related Companies and Tools


This page (NASDAQ:SLN) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners